| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
China Pharma Holdings, Inc.$8.1
+7.19 (+790.11%)
B 73Pipeline Score Undervalued Pharma · Commercial
Market Cap
30.78 M
EPS
-0.55
P/E Ratio
-
Value Trade
37.91 K
SEC Financials
Q1 2026Dilution Risk
Revenue
983.54 K
R&D Expenses
83.76 K
Operating CF
-55.29 K
Total Assets
45.14 M
Total Liabilities
8.12 M
Equity
37.02 M
D/E Ratio
12,345
-23.26 %
Week
14.26 %
1 Month
20.4 %
3 Month
-51.61 %
6 Month
-99.75 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
168.47 K
Monthly Burn
18.00 K
Runway
7.2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
93.61 M
52 Week Range
0.38 - 2.34
% held by Insiders
6.62 %
% held by Institutions
0.06 %
Enterprise Value
34.17 M
Total Shares
40.86 M
Short %
0.06 %
Float Shares
1.96 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for China Pharma Holdings, Inc.
24Total events
0Upcoming
2Tier-1 (high impact)
2006 – 2025Coverage
Event history 2
TBD
▼Reverse Stock SplitCorporate
Subscribe to view catalyst details
TBD
◆ATM ProgramCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B73
Pipeline Score $379M
Pipeline ValueUndervalued
Valuation Signal125
Drugs Scored12.3x
rNPV / MCap Top 96%
Micro Cap (rank 38 of 913)
Percentile RankChina Pharma Holdings, Inc. holds a solid B-grade pipeline (73/100), with $28.3B risk-adjusted pipeline value, led by SIBP-A13 formulation in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SIBP-A13 formulation Small molecule | Advanced Solid Tumor | Phase 1 | NCT06298058 | 10% | $4.2B | RECRUITING | 144 | STALLED | D (33) | Jun 30, 2026 | - | Jan 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CPHI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CPHI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CPHI▲ +790.1%today
China Pharma Holdings, Inc. Comments on Unusual Market Activity
China Pharma Holdings, Inc. addressed unusual market activity on July 21, 2026, stating that it was not aware of any material corporate developments to explain the fluctuations. The NYSE American contacted the company as part of its standard procedure. The company cautioned investors to rely on official filings and press releases for accurate information.
Read more →CPHI▼ -26.4%on this news· ran to -39% by day 3
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
China Pharma Holdings, Inc. announced it is unaware of any undisclosed information that could explain the unusual market activity in its stock observed on July 10, 13, and 15, 2026. The NYSE American contacted the company regarding this activity. The company maintains a diversified portfolio focused on high-incidence diseases in China.
Read more →CPHI▲ +24.4%on this news
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China,...
China Pharma Holdings, Inc. announced it is unaware of any undisclosed information that could explain the unusual market activity in its stock on May 12 and 13. The NYSE American contacted the company regarding this activity. The company maintains a strong market position with a diverse portfolio targeting critical health conditions in China.
Read more →CPHI▼ -7%on this news· ran to -46% by day 1
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split Haikou City, China
China Pharma Holdings Inc. has announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This decision was unanimously approved by the Company's Board and stockholders. Following the split, every 10 shares will convert into one share, without issuing fractional shares. This action is part of the Company's strategy to improve its stock price and overall market perception in a competitive landscape.
Read more →CPHI▼ -7%on this news· ran to -46% by day 1
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock...
China Pharma Holdings Inc. announced a 1-for-10 reverse stock split effective April 15, 2025. This decision was authorized by the Board of Directors and approved by stockholders. The split will convert every 10 shares into one, without issuing fractional shares. The company continues to focus on high-incidence diseases in China.
Read more →CPHI▼ -9.8%on this news
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a...
China Pharma Holdings, Inc. has successfully completed all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, LLC. This achievement enhances the company's financial stability and demonstrates its commitment to fiscal management. With the redemptions finalized, China Pharma aims to pursue growth and develop innovative pharmaceutical solutions for critical healthcare needs in China.
Read more →CPHIChina Pharma Announces the Entry of "At-The-Market" Equity Offering
China Pharma Holdings, Inc. has announced an at-the-market equity offering that allows the company to raise up to $600,000 by selling shares of common stock. A prospectus supplement has been filed with the U.S. Securities and Exchange Commission outlining the terms of the sale, including pricing conditions. The company’s investor may choose to purchase shares at their discretion between December 12, 2024, and December 31, 2024. However, there are no guarantees regarding the actual issuance or sale of any shares.
Read more →CPHIChina Pharma Announces the Entry of "At-The-Market" Equity Offering China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has ...
China Pharma Holdings, Inc. announced an at-the-market equity offering of up to $600,000 in common stock. The offering will be executed at the discretion of an investor over a specified period. The company aims to utilize the funds to support its operations and product development, although there are risks associated with the sale of shares.
Read more →CPHIChina Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated...
China Pharma Holdings, Inc. plans to launch its Dry Eye Disease Therapeutic Device in Q1 2025. The device aims to improve treatment for dry eye disease, which affects a significant portion of the Chinese population. The company has completed production and testing, positioning itself in a growing market projected to reach $579.51 million by 2030.
Read more →CPHIChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split Haikou City, China
China Pharma Holdings Inc. is implementing a 1-for-5 reverse stock split effective March 6, 2024, with trading set to begin on a split-adjusted basis on the NYSE American. The decision, approved by the Board of Directors and stockholders, aims to consolidate shares to improve market value. This split does not alter stockholders' percentage interests except for adjustments from fractional shares. The company continues to focus on developing products for major health issues in China.
Read more →CPHIChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock...
China Pharma Holdings Inc. announced a 1-for-5 reverse stock split effective March 6, 2024. This decision was approved by the Board of Directors and stockholders in late 2023. The split aims to consolidate shares, potentially improving market perception and attracting institutional investors. The company continues to focus on critical health conditions in China.
Read more →CPHI▲ +30.2%on this news
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated...
China Pharma Holdings, Inc. has announced that its Dry Eye Disease therapeutic device has successfully passed third-party testing. The company is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China, with expectations to launch in the first half of next year. The device aims to address a significant market gap in treating Dry Eye Disease, which affects millions globally.
Read more →CPHIChina Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that...
China Pharma Holdings, Inc. announced that its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., received approval for its candesartan tablets from the National Medical Products Administration of China. This approval indicates that the tablets meet the quality and efficacy standards required for generic drugs, allowing them to replace innovator drugs in clinical settings. The product is significant for managing hypertension and reducing risks associated with cardiovascular diseases.
Read more →CPHIChina Pharma Announces Receipt of Noncompliance Notice from NYSE American
Pharma Announces Receipt of Noncompliance Notice from NYSE American CITY, December 2, 2022 - China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notif
Read more →CPHI▼ -7%on this news
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency Haikou City, China
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency Haikou City, China - September 30, 2022 - China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "De
Read more →CPHIChina Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Announces Notification of NYSE American Listing Deficiency Haikou Ci
China Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Announces Notification of NYSE American Haikou City, China - September 12, 2017 - China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") tod
Read more →CPHIChina Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Reports Full Year 2016 Financial Results
China Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Reports Full Year 2016 Financial Results HAIKOU CITY, China, March 31, 2017 - China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Compa
Read more →CPHIChina Pharma Holdings, Inc. Announces Approval for NYSE Amex Listing
China Pharma Holdings, Inc. Announces Approval for NYSE Amex Listing HAIKOU CITY, China, September 28, 2009 - China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today ann
Read more →CPHICHARTER 2 cph8kex991082809.htm CHINA PHARMA HOLDINGS, INC. CHARTER OF THE NOMINATING AND COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (as of August 2 6 , 200 9 ) I. Purpose The Nominating and Compensation Committee (
CHINA PHARMA HOLDINGS, INC. CHARTER OF THE NOMINATING AND COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS The Nominating and Compensation Committee (the "Committee") of the Board of Directors of China Pharma Holdings, Inc. (the "Company") is established to: - Formulate
Read more →CPHIRESIGNATION LETTER Dear CPHI Board Members and Chairwoman Ms. Zhilin Li, Due to my personal reasons, I can not continue to serve as the Director and CFO of CPHI, there by I decided to resign as the Director and CFO of CP
Dear CPHI Board Members and Chairwoman Ms. Zhilin Li, Due to my personal reasons, I can not continue to serve as the Director and CFO of CPHI, thereby I decided to resign as the Director and CFO of CPHI. Simultaneously, thereby I decided to resign as the Director and CFO of Hain
Read more →CPHIChina Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million HAIKOU CITY, Hainan Province, China, May 28 2008 -- China Pharma Holdings, Inc. ("China Pharma" or "Company") (OTC BB: CPHI - News
cphi8kex991052108.txt -------------------------------------------------------------------------------- China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million HAIKOU CITY, Hainan Province, China, May 28 2008 -- China Pharma Holdings, Inc. ("
Read more →CPHIcph8kex991022508.txt PRESS RELEASE -------------------------------------------------------------------------------- China Pharma Holdings, Inc. Receives $5.6 Million in Purchase Orders for Pusen OK (Generic Aleve-D(TM) P
cph8kex991022508.txt -------------------------------------------------------------------------------- China Pharma Holdings, Inc. Receives $5.6 Million in Purchase Orders for Pusen OK (Generic Aleve-D(TM) Product) The Company announces unaudited preliminary 2007 revenue of a
Read more →CPHICrocker Coulson Donald Xu President Vice President, Strategic Planning CCG Elite China Pharma Holdings, Inc. 310 231-8600 ext 103 858-776-8880 crocker.coulson@ccgir.com dxu@chinapharmaholdings.com --------------
cph8kex991020107.txt PRESS RELEASE DATED FEBRUARY 6, 2007 Crocker Coulson Donald Xu President Vice President, Strategic Planning CCG Elite China Pharma Holdings, Inc. 310 231-8600 ext 103 858-776-8880 crocker.coulson@ccgir.com dxu@chinapharmaholdings.com ------------------
Read more →CPHIcph8kex991090606.txt PRESS RELEASE DATED AUGUST 15, 2006 Contact: Crocker Coulson Donald Xu President Vice President, Strategic Planning CCG Elite China Pharma Holdings, Inc. 310 231-8600 ext 103 858-776-8880 crocker.cou
cph8kex991090606.txt PRESS RELEASE DATED AUGUST 15, 2006 Crocker Coulson Donald Xu President Vice President, Strategic Planning CCG Elite China Pharma Holdings, Inc. 310 231-8600 ext 103 858-776-8880 crocker.coulson@ccgir.com dxu@chinapharmaholdings.com China Pharma Holdin
Read more →CPHICERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF TS ELECTRONICS, INC. _________________________________ Pursuant to Section 242 of the General Corporation Law of the State of Delaware TS Electronics, Inc., a c
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF TS ELECTRONICS, INC. _________________________________ Pursuant to Section 242 of the General Corporation Law of the State of Delaware TS Electronics, Inc., a corporation organized and existing under and by virtue
Read more →CPHITS ELECTRONICS, INC. INDEX TO FINANCIAL STATEMENTS ONNY INVESTMENT LIMITED AND SUBSIDIARY REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM......................F-2 BALANCE SHEETS...................................
AUDITED FINANCIAL STATEMENTS TS ELECTRONICS, INC. INDEX TO FINANCIAL STATEMENTS ONNY INVESTMENT LIMITED AND SUBSIDIARY REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM......................F-2 BALANCE SHEETS.............................................................
Read more →Competitive Position
How CPHI ranks across every disease it competes inCompetitive Position is a premium feature
See how CPHI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial